Caxton Associates LP Decreases Stake in Masimo Co. (MASI)

Caxton Associates LP decreased its position in Masimo Co. (NASDAQ:MASI) by 12.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,400 shares of the medical equipment provider’s stock after selling 600 shares during the quarter. Caxton Associates LP’s holdings in Masimo were worth $381,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Prudential Financial Inc. grew its position in shares of Masimo by 14.4% in the second quarter. Prudential Financial Inc. now owns 553,215 shares of the medical equipment provider’s stock valued at $50,442,000 after purchasing an additional 69,810 shares during the last quarter. State Street Corp grew its position in shares of Masimo by 10.4% in the second quarter. State Street Corp now owns 1,547,728 shares of the medical equipment provider’s stock valued at $141,121,000 after purchasing an additional 146,212 shares during the last quarter. American Century Companies Inc. grew its position in shares of Masimo by 98.0% in the second quarter. American Century Companies Inc. now owns 209,474 shares of the medical equipment provider’s stock valued at $19,100,000 after purchasing an additional 103,656 shares during the last quarter. D L Carlson Investment Group Inc. grew its position in shares of Masimo by 32.4% in the second quarter. D L Carlson Investment Group Inc. now owns 46,240 shares of the medical equipment provider’s stock valued at $4,216,000 after purchasing an additional 11,315 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its position in shares of Masimo by 27.1% in the second quarter. Robeco Institutional Asset Management B.V. now owns 1,095,353 shares of the medical equipment provider’s stock valued at $99,872,000 after purchasing an additional 233,412 shares during the last quarter. 83.74% of the stock is currently owned by institutional investors.

Shares of Masimo Co. (NASDAQ:MASI) opened at $84.66 on Friday. The stock has a market capitalization of $4,410.00, a P/E ratio of 32.61, a P/E/G ratio of 2.87 and a beta of 0.72. Masimo Co. has a 12 month low of $64.29 and a 12 month high of $104.71.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.17. The business had revenue of $193.69 million during the quarter, compared to analysts’ expectations of $189.01 million. Masimo had a return on equity of 22.17% and a net margin of 45.83%. The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.52 earnings per share. equities analysts expect that Masimo Co. will post 2.95 EPS for the current fiscal year.

In related news, Director Steven Barker sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total value of $900,000.00. Following the completion of the sale, the director now directly owns 73,249 shares in the company, valued at $6,592,410. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Yongsam Lee sold 13,976 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $89.43, for a total value of $1,249,873.68. Following the completion of the sale, the executive vice president now owns 74,000 shares of the company’s stock, valued at $6,617,820. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,074 shares of company stock valued at $4,737,245. 16.60% of the stock is currently owned by corporate insiders.

Several equities analysts have recently commented on MASI shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $108.00 target price on shares of Masimo in a research report on Friday, November 3rd. Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $98.00 target price on the stock in a research report on Thursday, November 2nd. Finally, BidaskClub cut Masimo from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Masimo has an average rating of “Hold” and a consensus price target of $97.17.

ILLEGAL ACTIVITY NOTICE: This story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.com-unik.info/2017/12/15/caxton-associates-lp-decreases-stake-in-masimo-co-masi.html.

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit